Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia
| Autor: | Jose J. Lorenzo, Lionel de Lumley, Ian Hann, R. Musso, Brigitte Pautard, Stefan Kuhle, M. Vicariot, Mark Winter, Jørgen Ingerslev, Stefan Lethagen, Omer Devecioglu, Edith Fressinaud, Roseline d'Oiron, Alison Street, Majorlein Peters, Natascha Nohe, Mario von Depka, Hervé Chambost, Pantelis E. Makris, Angela Huth-Kühne, Jonathan Wilde, Man-Chiu Poon, Patricia Paugy, Howard A. Britton, Massimo Morfini, Willem Gerrits, Christel Van Geet, Donald S. Houston, Marie-Francoise Torchet, Angela Thomas, Christiane Guthner, Alain Marques-Verdier, Claire Berger, Lilian Tengborn, A. Karafoulidou, Pia Petrini, Christine Demers, Philippe Beurrier, Nathalie Trillot, Gabriele Strauss, Claude Negrier |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Male
medicine.medical_specialty medicine.medical_treatment Platelet disorder Factor VIIa Platelet Transfusion Surgical prophylaxis chemistry.chemical_compound Thrombasthenia Pregnancy Internal medicine medicine Humans Platelet Chemotherapy Factor VII biology business.industry Coagulants Pregnancy Complications Hematologic Hematology Recombinant Proteins Surgery Platelet transfusion chemistry Recombinant factor VIIa biology.protein Female business |
| Zdroj: | Seminars in hematology. 38(4 Suppl 12) |
| ISSN: | 0037-1963 |
| Popis: | Recombinant factor VIIa (rFVIIa; NovoSeven ® , Novo Nordisk, Bagsvaerd, Denmark) appears effective and relatively safe for the treatment of bleeding and for surgical prophylaxis in patients with Glanzmann thrombasthenia as reported to the International Registry on rFVIIa and Congenital Platelet Disorders. One of the shortcomings of the Registry data is the heterogeneity of treatment protocol, including dosage, number of doses used, duration of treatment before declaration of failure, and mode of rFVIIa administration (bolus v continuous infusion). The data are not yet sufficient to define optimal regimens for various indications such as the type of bleeding or the type of procedures. The place of this drug compared to platelet transfusion in the overall management of patients with Glanzmann thrombasthenia will need to be determined in relationship to a number of challenges and unresolved issues in the clinical care of these patients. These issues include: how to improve local measures for patients with mucosal bleeds, optimal management of young women during menarche, optimal platelet transfusion regimens for various indications, the relationship between antiplatelet antibodies detected by monoclonal antibody-specific immobilization of platelet antigens (MAIPA) and effectiveness of platelet transfusion, whether there are other biological tests that may correlate with effectiveness of platelet transfusion, and management of pregnancy and delivery regarding antiplatelet immunization. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|